Sarepta Gains After Pfizer Suffers A Setback With Gene Therapy For DMD – Sarepta Therapeutics, Inc. (NASDAQ:SRPT)


Sarepta Therapeutics (SRPT) continues to make solid traction with respect to its gene therapy candidate micro-dystrophin for treating patients with Duchenne muscular dystrophy (DMD). It has seen positive preliminary evidence that its product works in treating this disease. The biggest concern for Sarepta was that Pfizer (PFE) would come outRead More →